Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 144 publications
Definition of Severity and Relapse for Vitiligo: An International Consensus Statement.
Journal: JAMA dermatology
Published: March 25, 2026
Activatable photoimmunotherapy enables spatiotemporal depletion of pathogenic cells in immune-driven disease and cancer.
Journal: The Journal of investigative dermatology
Published: February 27, 2026
AAVrh32.33 capsid demonstrates unexpected dermal tropism regardless of immunodominant epitope.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: January 22, 2026
Impact of treatment duration on response durability: A post hoc analysis of the double-blind, vehicle-controlled, randomized TRuE-V long-term extension study of ruxolitinib cream in vitiligo.
Journal: Journal of the American Academy of Dermatology
Published: November 13, 2025
Prolonged ruxolitinib cream treatment for vitiligo among patients with no or limited response in the first 6 months.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: November 07, 2025
A Spatially Coordinated Keratinocyte-Fibroblast Circuit Recruits MMP9+ Myeloid Cells to Drive IFN-I-Driven Inflammation in Photosensitive Autoimmunity.
Journal: bioRxiv : the preprint server for biology
Published: September 02, 2025
Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo.
Journal: Dermatology and therapy
Published: August 04, 2025
A spatially coordinated keratinocyte-fibroblast circuit recruits MMP9+ myeloid cells to drive type I interferon-driven inflammation in photosensitive autoimmunity.
Journal: Nature immunology
Published: August 04, 2025
Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study.
Journal: The British journal of dermatology
Published: June 25, 2025
Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study.
Journal: The British journal of dermatology
Published: June 25, 2025
Intradermal delivery of lipophilic siRNAs enables prolonged skin retention and sustained gene silencing in a porcine model.
Journal: Nature communications
Published: June 19, 2025
Last Updated: 09/26/2026